The coronavirus outbreak is unlikely to impact the finished pharma products in India, as least for the next four-five months, said Sudarshan Jain, secretary-general of Indian Pharmaceutical Alliance (IPA).
“Prices of every product in the Indian industry is controlled so the raw material prices may go up but finished product prices do not go up,” said Jain in an interview with CNBC-TV18.
India is preparing itself for the potential supply disruption and shortage of key pharma ingredients due to the coronavirus outbreak.
Jain further said that most large pharma companies have inventory planned due to the Chinese New Year. “We expect inventory levels to improve hereon,” said Jain.
Talking about the meeting with Niti Aayog CEO Amitabh Kant, he said, “One of the good point in yesterday’s meeting where environmental secretary was also present… he said that he will expedite environmental clearance, if any change in foreign mix is required, his office is involved and if there are any issues which small scale manufacturing are facing in any part of the country, they will be viewed. So that is a very proactive step by the government.”